Market Overview - On the first trading day of August, the A-share market experienced overall weakness, with major sectors such as oil and petrochemicals, semiconductors, and non-bank financials adjusting, leading to declines in the three major stock indices [2] - The Shanghai Composite Index closed at 3559.95 points, down 0.37%; the Shenzhen Component Index closed at 10991.32 points, down 0.17%; and the ChiNext Index closed at 2322.63 points, down 0.24% [2] - The total trading volume in the Shanghai and Shenzhen markets was 15,983 billion yuan, a decrease of over 3,300 billion yuan compared to the previous trading day [2] Solar Equipment Sector - The solar equipment sector showed strong performance, with the Shenwan Solar Equipment Index closing up 2.60%, leading all secondary industries [3] - Companies such as Jiejia Weichuang and Shuangliang Energy reached the daily limit [3] - The Ministry of Industry and Information Technology recently issued a special energy-saving inspection task list for the polysilicon industry for 2025, requiring local authorities to implement and report results by September 30 [3] - According to China International Capital Corporation (CICC), this move is aimed at optimizing the supply side of the industry and may lead to the exit of backward production capacity, particularly affecting the upstream polysilicon segment [3] Express Delivery Sector - The express delivery sector also performed actively, with the Shenwan Logistics Index rising by 1.53% [3] - Companies such as YTO Express, Shentong Express, and Yunda Holdings saw increases of over 6%, while other stocks like Debang Logistics also followed suit [3] - On July 29, the State Post Bureau held a meeting with express delivery companies to address issues related to "involution" competition and promote high-quality industry development [4] Innovative Drug Sector - The innovative drug sector remained active, with stocks like Weikang Pharmaceutical hitting a 20% daily limit, and companies such as Anglikang and Guizhou Bailin recording consecutive gains [5] - Recent announcements from companies like Haizike and Huahai Pharmaceutical regarding new drug applications have contributed to the sector's momentum [5] - According to Dongfang Securities, the global innovative drug field is shifting from "Made in China" to "Created in China," with domestic pharmaceutical companies enhancing their international competitiveness [5] Dividend and Resource Sectors - Looking ahead to August, the strategy team at Industrial Securities suggests focusing on dividend sectors and resource industries for investment opportunities [6] - Historical data indicates that the first half of August typically sees fewer companies disclosing semi-annual results, leading to a higher success rate for small-cap stocks [6] - As the month progresses and companies begin to report earnings, larger-cap stocks with earnings certainty are expected to gain more attention, particularly in resource sectors like coal and petrochemicals [6]

Core Viewpoint - The innovative drug concept has shown strong performance recently, with several companies experiencing significant stock price increases, indicating a positive market sentiment towards the sector [1] Group 1: Stock Performance - Companies such as Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, Xintian Pharmaceutical, and Fuyuan Pharmaceutical have reached their daily price limits [1] - Other companies like Anglikang, Rejing Bio, Kexing Pharmaceutical, and Yuekang Pharmaceutical have seen stock price increases exceeding 5% [1] Group 2: Regulatory Approvals - On July 31, Haizhi Pharmaceutical announced that its innovative drug HSK3486 (环泊酚注射液) has received acceptance for its FDA listing application [1] - On the same day, Huahai Pharmaceutical reported that its subsidiaries Huao Tai and Huabo Bio's dual-target drug HB0043, aimed at IL-17A and IL-36R, has received clinical trial approval from the National Medical Products Administration [1]

Group 1: Public Health Response - The 2025 version of the Chikungunya fever diagnosis and treatment plan has been released to enhance the standardized treatment level across various medical institutions in China [1] - The release reflects China's heightened vigilance towards imported infectious diseases, as there is currently no vaccine available for the virus [1] Group 2: Company Control Changes - Renfu Pharmaceutical announced a change in its actual controller to China Merchants Group, following the completion of board restructuring and control acquisition [2] - This change is expected to stabilize the company's governance structure and promote resource integration [2] Group 3: Drug Development and Approvals - Huahai Pharmaceutical's HB0043, a dual-target antibody drug, has received clinical trial approval, marking it as the first of its kind targeting IL-17A and IL-36R [3][4] - CS231295 from Microchip Biotech has received FDA approval for clinical trials, showcasing its potential in treating brain tumors due to its ability to penetrate the blood-brain barrier [4] - Shuyou Shen has obtained a summary report for BDB-001 injection, demonstrating significant clinical advantages in reducing steroid dosage for ANCA-associated vasculitis [5]

Group 1 - The National Health Commission and the National Administration of Traditional Chinese Medicine released the 2025 version of the Chikungunya fever diagnosis and treatment plan to enhance standardized treatment levels [1] - The new treatment plan reflects China's heightened vigilance towards imported infectious diseases, as there is currently no vaccine available for the virus [1] Group 2 - Renfu Pharmaceutical announced a change in its actual controller to China Merchants Group, with China Merchants Biomedical controlling approximately 4.34 billion shares, accounting for 26.62% of the total share capital [2] - The change in control is expected to stabilize the company's governance structure and promote resource integration [2] Group 3 - Huahai Pharmaceutical's HB0043, the world's first dual-target antibody drug targeting IL-17A and IL-36R, has received clinical trial approval from the National Medical Products Administration [3] - HB0043 shows stronger efficacy than monoclonal antibodies in various animal disease models, indicating its potential for treating autoimmune diseases [3] Group 4 - Microchip Biotech received FDA approval for the clinical trial of CS231295, a selective AuroraB inhibitor for treating advanced solid tumors, highlighting its ability to penetrate the blood-brain barrier [4] - The approval signifies a differentiated innovation capability in the field of brain tumor treatment, where most drugs struggle to cross the blood-brain barrier [4] Group 5 - Shutaishen obtained a summary report for the I/II phase clinical study of BDB-001 injection for ANCA-associated vasculitis, showing significant clinical advantages in steroid reduction and complete remission rates [5] - The company plans to advance to phase III clinical trials to further validate the clinical benefits for AAV patients [5]

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of its drug HB0043, which targets pyogenic hidradenitis [1][2]. Drug Basic Information - Drug Name: Injectable HB0043 - Indication: Pyogenic Hidradenitis - Dosage Form: Injectable Sterile Powder - Application: Clinical Trial - Applicants: Shanghai Huatai Biopharmaceutical Co., Ltd. and Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd. [1] Additional Drug Information - In May 2025, Huatai received approval from New Zealand's Medicines and Medical Devices Safety Authority to conduct Phase I clinical trials for HB0043 in New Zealand [1]. - The total R&D investment in the project has reached approximately RMB 69.09 million [3]. Drug Mechanism and Advantages - HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [3]. - Compared to monoclonal antibodies, HB0043 shows stronger efficacy in inhibiting cytokine-induced inflammation and fibrosis through dual blockade of IL-17A and IL-36R [3]. - It has proven superior efficacy in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [3]. - HB0043 is the first bispecific drug targeting IL-17A and IL-36R globally, potentially overcoming the limitations of existing single-target therapies [4].

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its drug HB0043, which targets pyogenic hidradenitis and represents a significant advancement in the treatment of autoimmune diseases [1][2]. Group 1: Drug Information - The drug HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [2]. - HB0043 has shown superior efficacy compared to monoclonal antibodies in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [2]. - The drug is expected to provide new therapeutic strategies for immune-mediated inflammatory skin diseases and fibrotic diseases, addressing the limitations of single-factor blocking therapies [2][3]. Group 2: Clinical Trial Approval - The drug has received approval for clinical trials, with the first phase set to take place in New Zealand, as approved by the Ethics Committee [1]. - The company has invested approximately RMB 69.09 million in the research and development of HB0043 to date [2]. Group 3: Competitive Advantage - HB0043 is the first bispecific antibody globally targeting both IL-17A and IL-36R, potentially overcoming the limitations of existing single-target therapies [3]. - The drug is positioned to be widely applicable in various Th17/IL-36 related immune-mediated diseases, showcasing a first-in-class advantage in its mechanism and potential [3].

（文章来源：证券日报） 证券日报网讯 7月31日晚间，华海药业发布公告称，近日，公司的下属子公司上海华奥泰生物药业股份 有限公司和华博生物医药技术（上海）有限公司收到国家药品监督管理局核准签发的注射用HB0043的 《药物临床试验批准通知书》。 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 | 2025-086 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于下属子公司获得药物临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）的下属 子公司上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）和华博生物医药技 术（上海）有限公司（以下简称"华博生物"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的注射用 HB0043 的《药物临床试验批准通知书》。现将相 关情况公告如下： 适应症：化脓性汗腺炎 剂型：注射用无菌粉末 申请事项：临床试验 申请人：上海华奥泰生物药业股份有限公司；华博生物医药技术（上海）有限公 司 结论：同意开展临床试验 二、药物的其他相关情况 2025 年 5 月，公司下属子公司华奥泰获得新西兰药品和医疗器械 ...

Core Insights - Huahai Pharmaceutical's subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HB0043, a bispecific antibody targeting IL-17A and IL-36R, aimed at treating various autoimmune diseases [1][2] Group 1: Product Development - HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [1] - The drug has shown superior efficacy compared to monoclonal antibodies in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [1] Group 2: Market Potential - As the first bispecific drug targeting IL-17A and IL-36R globally, HB0043 is expected to overcome the limitations of existing single-target therapies [2] - Current therapies targeting IL-17A and IL-36R have shown positive effects in multiple indications, but there are still shortcomings in addressing inflammation in some patients [2] - HB0043's innovative dual-target approach is anticipated to have broad applications in various Th17/IL-36 related immune-mediated diseases, showcasing a first-in-class advantage [2]